Aviation Medication Transparency Act of 2026

Core Policy Mechanism Top 1

FAA Medication Transparency List Publication Requirement

Requires the Federal Aviation Administration (FAA) to publish and keep updated a public list of medications approved or prohibited for pilots and air traffic controllers seeking medical certification, including safe-use conditions, contraindications, and 'Do Not Fly' designations.

• Population Scope Low Directly affects the comparatively small population of certified or aspiring pilots, air traffic controllers, and their treating physicians — well under 1% of the U.S. population.
• Budgetary Magnitude Low No funds are authorized or appropriated; the bill imposes only an administrative publication duty on the Federal Aviation Administration (FAA) with no independent funding mechanism.
• Legal / Regulatory Depth Medium Creates a new statutory procedural duty — FAA must compile, publish, and maintain a medication list with prescribed content and dissemination requirements — but does not alter substantive certification standards or create new enforceable rights for applicants.
• Degree of Discretion Granted Medium Mandatory 'shall' language governs the core publication obligation, but FAA retains meaningful discretion in list content, update timing tied to policy changes, and the catch-all authority to include 'any other information the Administrator determines appropriate.'
• Implementation & Enforcement Burden Low Imposes an affirmative administrative publication obligation with no penalties, no new enforcement machinery, and no compliance regime — burden falls entirely on internal FAA staff effort to compile and maintain the list.
• Temporal Commitment High The publication and maintenance duty is ongoing with no sunset or reauthorization trigger, persisting indefinitely until Congress affirmatively acts to repeal or amend it.